<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02998697</url>
  </required_header>
  <id_info>
    <org_study_id>LB.02.01/VII/077/KEP.033EV</org_study_id>
    <nct_id>NCT02998697</nct_id>
  </id_info>
  <brief_title>Short Term Oral Iron Supplementation in Systolic Heart Failure Patients Suffering From Iron Deficiency Anemia</brief_title>
  <acronym>IRON5</acronym>
  <official_title>The Effect of Short Term Oral Iron Supplementation in Systolic Heart Failure Patients Suffering From Iron Deficiency Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cardiovascular Center Harapan Kita Hospital Indonesia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cardiovascular Center Harapan Kita Hospital Indonesia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of Ferrous Sulphate (FS) tablets in
      improving iron stores and functional capacity in HF patients with Iron Deficiency Anemia
      (IDA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators conducted a double blind randomized controlled trial (RCT) enrolling 54
      Heart Failure (HF) patients (LVEF &lt; 50%) with IDA (Ferritin &lt; 100 ng/mL or 100-300 ng/mL with
      Tsat &lt; 20%) at outpatient clinic of National Cardiovascular Center Harapan Kita from January
      to July 2016. Patients were randomized 1:1 to received FS or placebo for 90 days, the
      investigators then evaluated the change in 6-Minute Walking Test (6MWT) distance as primary
      end-point and changes on N-Terminal-pro Brain Natriuretic Peptide (NT-proBNP) and post 6MWT
      serum lactate levels as secondary end-points.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Functional Capacity</measure>
    <time_frame>90 days</time_frame>
    <description>Six Minute Walk Test (meter)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ferritin</measure>
    <time_frame>90 days</time_frame>
    <description>Ferritin level (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transferrin saturation</measure>
    <time_frame>90 days</time_frame>
    <description>Transferrin saturation (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haemoglobin</measure>
    <time_frame>90 days</time_frame>
    <description>Haemoglobin level (gr/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiography parameters</measure>
    <time_frame>90 days</time_frame>
    <description>Left Ventricle Ejection Fraction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N Terminal-pro Brain Natriuretic Peptide</measure>
    <time_frame>90 days</time_frame>
    <description>NT-proBNP level (pg/mL)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Heart Failure, Systolic</condition>
  <condition>Iron-deficiency Anemia</condition>
  <arm_group>
    <arm_group_label>Treated Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Systolic heart failure patients received Ferrous Sulfate 200 mg t.i.d for 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Systolic heart failure patients received placebo oral capsule t.i.d for 90 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferrous Sulfate</intervention_name>
    <description>Ferrous sulfate 200 mg t.i.d for 90 days</description>
    <arm_group_label>Treated Group</arm_group_label>
    <other_name>Ferrous Sulfate oral capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Capsule</intervention_name>
    <description>Lactose 200 mg t.i.d for 90 days</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 year old

          -  Systolic heart failure patients without clinical sign of decompensation at outpatient
             clinic

          -  New York Heart Association (NYHA) functional class II-III able to perform 6MWT

          -  LVEF &lt; 50%

          -  On heart failure therapy

          -  Haemoglobin (Hb) &lt; 13 gr/dL (male); Hb &lt; 12 gr/dL (female) and &gt; 8 gr/dL

          -  Ferritin &lt; 100 µg/L or Ferritin 100-300 µg/L dengan Transferrin saturation (Tsat) &lt;
             20%

          -  Agree to participate

        Exclusion Criteria:

          -  History of : active bleeding,infection, malignancy, haematological abnormality, peptic
             ulcer

          -  History of myocardial revascularization (CABG/PCI) within 3 month

          -  Acute Coronary Syndrome (ACS), stroke,Transient Ischemic Attack (TIA) within 3 month

          -  Know to have allergic reaction to Ferrous sulfate

          -  History of intravenous iron administration within 1 month

          -  Permanent Pace Maker(PPM)/Implantable Cardiac Defibrillator (ICD)/Cardiac
             Resynchronization Therapy (CRT)

          -  estimated Glomerular Filtration Rate (eGFR) &lt; 30 ml/min/1.73m2

          -  NT-proBNP &gt; 4000 pg/ml (for patients without baseline data) or decreased level of
             NT-proBNP &lt; 30% from baseline

          -  Increase level of serum alanine aminotransferase (ALT)/ serum aspartate
             aminotransferase (AST)&gt; 3x normal value

          -  Moderate to severe primary valvular heart disease

          -  Congenital heart disease

          -  Right heart failure due to primary pulmonary hypertension, cor pulmonale, Chronic
             Thrombo-Embolic Pulmonary Hypertension (CTEPH)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bambang B Siswanto, Professor</last_name>
    <role>Study Director</role>
    <affiliation>National Cardiovascular Center Harapan Kita</affiliation>
  </overall_official>
  <results_reference>
    <citation>Niehaus ED, Malhotra R, Cocca-Spofford D, Semigran M, Lewis GD. Repletion of Iron Stores With the Use of Oral Iron Supplementation in Patients With Systolic Heart Failure. J Card Fail. 2015 Aug;21(8):694-7. doi: 10.1016/j.cardfail.2015.05.006. Epub 2015 May 29.</citation>
    <PMID>26028263</PMID>
  </results_reference>
  <results_reference>
    <citation>Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P; FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009 Dec 17;361(25):2436-48. doi: 10.1056/NEJMoa0908355. Epub 2009 Nov 17.</citation>
    <PMID>19920054</PMID>
  </results_reference>
  <results_reference>
    <citation>McDonagh T, Macdougall IC. Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral? Eur J Heart Fail. 2015 Mar;17(3):248-62. doi: 10.1002/ejhf.236. Epub 2015 Jan 30. Review.</citation>
    <PMID>25639592</PMID>
  </results_reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2016</study_first_submitted>
  <study_first_submitted_qc>December 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2016</study_first_posted>
  <last_update_submitted>December 19, 2016</last_update_submitted>
  <last_update_submitted_qc>December 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cardiovascular Center Harapan Kita Hospital Indonesia</investigator_affiliation>
    <investigator_full_name>Lita Dwi Suryani</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Systolic Heart Failure</keyword>
  <keyword>Anemia</keyword>
  <keyword>Iron Deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
    <mesh_term>Deficiency Diseases</mesh_term>
    <mesh_term>Heart Failure, Systolic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

